CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 73 enrolled
Drug / intervention
Tesamorelindrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02572323
NCT02572323Phase 2Completed
CompareCT.gov

Phase II Trial of Tesamorelin for Cognition in Aging HIV-Infected Persons

University of California, San Diego·interventional·Posted Oct 8, 2015·Updated Mar 12, 2026

In Brief

A Phase 2 clinical trial evaluating Tesamorelin for Mild Cognitive Impairment. Completed, enrolled 73 participants across 4 sites.

Detailed Summary

The aim of this study is to test whether tesamorelin, in combination with a text-messaging application to help with motivation and adherence, will significantly improve memory and thinking in HIV.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMild Cognitive Impairment
CountriesUnited States
CollaboratorsUniversity of Southern California, PalmTree Clinical Research Inc., University of California, San Francisco

Timeline

Phase 2CompletedFinished
20162017201820192020202120222023202420252026
First PostedOct 8, 2015
Enrollment StartFeb 15, 2017
Primary CompletionOct 15, 2023
TodayJul 2, 2026
Enrollment to primary: 6.7 yearsPosted 10.7 years ago

Interventions

Tesamorelindrug

Tesamorelin is an injectable medication already approved by the U.S. FDA to treat abdominal fat accumulation in HIV